For the Quarter Ending September 2025
North America
• In United States, the Famotidine Price Index rose quarter-over-quarter in Q3 2025, driven by significant increases in production costs.
• Famotidine production costs increased in Q3 2025, due to a 2.6% year-over-year PPI rise in August 2025 and higher energy prices.
• Demand for Famotidine faced mixed signals, with robust retail sales (5.42% YoY in September 2025) offset by declining consumer confidence.
• The Famotidine Price Index experienced upward pressure, reflecting a 3.0% year-over-year CPI increase in September 2025 and rising input expenses.
• Overall manufacturing activity contracted in Q3 2025, and broader economic conditions deteriorated, impacting the chemical market.
• US natural gas prices strengthened year-over-year in Q3 2025, raising feedstock and wholesale power costs for chemical production.
• Chemical inventories tightened in Q3 2025 due to accelerated destocking, while US chemical exports and imports decreased in July 2025.
• A 4.3% unemployment rate in September 2025 supported consumer disposable income, positively influencing demand for healthcare products.
Why did the price of Famotidine change in September 2025 in North America?
• Rising production costs, with a 2.6% YoY PPI increase in August 2025, impacted Famotidine pricing.
• Increased energy and raw material expenses, as US natural gas prices strengthened in Q3 2025, raised costs.
• Mixed demand signals, including 5.42% YoY retail sales in September 2025, influenced market.
APAC
• In China, the Famotidine Price Index fell quarter-over-quarter in Q3 2025, driven by declining production costs and elevated industry overcapacity.
• Famotidine production costs decreased as the Producer Price Index declined 2.3% in September 2025 and international crude oil prices weakened.
• Demand for Famotidine was supported by a 6.5% rise in industrial production and 3.0% growth in retail sales in September 2025.
• However, the Manufacturing Index was contracting in September 2025, and consumer confidence was 89.6, tempering overall demand.
• Industry overcapacity in the broader chemical sector remained elevated in Q3 2025, following significant capacity additions.
• China's API market share expanded in Q3 2025, bolstered by government incentives and surging high-tech manufacturing output.
• Healthcare spending strengthened in China in 2025, supported by increased government funding for public health services.
• International crude oil prices gradually weakened in Q3 2025, reducing energy and feedstock costs for Famotidine production.
Why did the price of Famotidine change in September 2025 in APAC?
• The Producer Price Index declined 2.3% in September 2025, and international crude oil prices weakened, lowering production costs.
• Elevated industry overcapacity and significantly increased chemical production capacity in Q3 2025 created downward price pressure.
• A contracting Manufacturing Index in September 2025 and consumer confidence at 89.6 tempered demand, influencing prices.
Europe
• In Germany, Famotidine Price Index remained stable in Q3 2025, balancing demand and cost pressures.
• Famotidine production costs saw downward pressure from a 1.7% decline in producer prices in September 2025.
• Elevated energy and raw material costs, plus high carbon allowance costs, challenged Famotidine production in Q3 2025.
• Famotidine demand outlook was supported by strengthening pharmaceutical demand and stable 0.2% retail sales in September 2025.
• Consumer purchasing power for OTC Famotidine was impacted by a 2.4% CPI increase, despite stable 6.3% unemployment.
• German industrial production declined 1.0% in September 2025, reflecting a contracting manufacturing index in Q3 2025.
• European natural gas prices trended downwards through September 2025, though German prices inched up.
• US tariffs significantly impacted German pharmaceutical exports in July 2025, affecting trade flows.
• The Famotidine Price Index forecast suggests continued stability, influenced by ongoing demand and cost dynamics.
Why did the price of Famotidine change in September 2025 in Europe?
• Strengthening pharmaceutical demand in Q3 2025 supported consumption, despite a 2.4% CPI increase.
• Producer prices declined 1.7% in September 2025, but chemical energy and raw material costs remained elevated.
• German industrial production fell 1.0% in September 2025; US tariffs impacted exports.
